Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 3.6% in the afternoon session after the company announced it ...
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc. (Nasdaq: RVMD) released topline Phase 3 results from its RASolute 302 trial, effectively setting a new standard of care in the treatment of pancreatic cancer. For [...]
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche oncology sub-specialty into a multi-billion-dollar cornerstone of precision medicine. Headquartered in Melbourne, Australia, with a significant and growing footprint in the United States and [...]
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an industry often characterized by volatile "one-hit wonders" and aggressive M&A cycles, Regeneron has carved out a unique identity as a founder-led, R&D-centric powerhouse. Currently, [...]
Eli Lilly (LLY) exemplifies the GARP strategy with strong growth, reasonable valuation relative to peers, and robust profitability for sustainable returns.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 4.5% in the afternoon session after CEO Andy Jassy's annual s...
In a move that has sent shockwaves through the global consumer staples market, Unilever (NYSE:UL) and McCormick & Company (NYSE:MKC) have officially entered into a definitive agreement to merge Unilever’s expansive global food business with the Maryland-based spice giant. The $65 billion transaction, announced on March 31, 2026,
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the company’s Phase 3 ATTAIN clinical trial program has revealed that its experimental oral medication, Orforglipron, achieved a staggering
Some large merger & acquisition deals that could shake up the consumer goods and the food distribution industry, plus deals in the healthcare industry.
